U.S. NEUROSTIMULATION DEVICES MARKET
167 Pages | 49 Exhibits | 2013 Analysis | Forecasts Through 2017
Despite the lingering economic uncertainty and budgetary constraints that have restrained other medical device markets, the U.S. market for neurostimulation devices is expected to experience double-digit growth due to several factors, including cost-efficiency, strong reimbursement and device replacement sales. Growth is supported by continued success and strong demand for leading neurostimulation systems developed by major competitors including Medtronic, Boston Scientific, St. Jude Medical, Cyberonics and Cochlear, Ltd. that provide safe and effective long-term therapies for a large, diversified and aging population of patients who suffer from intractable/refractory conditions such as epilepsy, chronic pain of the trunk or limbs, incontinence and Parkinson's disease. New, exciting applications will help expand the market over the next decade, including those that may treat certain forms of blindness; severe, refractory chronic migraine; morbid obesity; and obstructive sleep apnea, among other indications.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include neurostimulation devices for the core treatment areas: chronic intractable pain, dystonia/essential tremor/Parkinson's disease, refractory epilepsy, gastroparesis, profound hearing loss, urinary (overactive bladder) and fecal incontinence, as well as several emerging applications, including blindness, chronic migraine, treatment-resistant depression, heart failure, obesity, sleep apnea (obstructive), foot drop, paralysis, stroke and tinnitus, among others. The report also discusses a handful of emerging noninvasive stimulation technologies, such as peripheral nerve stimulation for the treatment of chronic pain.
Publisher: Medtech Insight
EXECUTIVE SUMMARY i. Implantable Neurostimulation Devices Market a. Market Forecast ii. Methodology Exhibit ES-1: Estimated Prevalence of Selected Neurological Conditions Exhibit ES-2: Selected Advantages and Disadvantages of Neurostimulation Therapy Exhibit ES-3: Estimated Number of Neurostimulation Implants, by Selected Neurological Condition Exhibit ES-4: Selected Market Drivers and Limiters for Implantable Neurostimulation Devices Exhibit ES-5: Implantable Neurostimulation Devices (Including Cochlear Implants), Combined Market Forecast 2012-2017 Exhibit ES-6: Implantable Neurostimulation Devices (Excluding Cochlear Implants), Combined Market Forecast, 2012-2017 Exhibit ES-7: Cochlear Implants, Market Forecast, 2012-2017 1. NEUROSTIMULATION TECHNOLOGIES OVERVIEW 1.1 Implantable Neurostimulators 1.1.1 Deep Brain Stimulators 1.1.2 Gastric Nerve Stimulators 1.1.3 Sacral Nerve Stimulators 1.1.4 Spinal Cord Stimulators 1.1.5 Vagus Nerve Stimulators 1.1.6 Cochlear Implants Exhibit 1-1: Estimated Prevalence of Selected Neurological Conditions Exhibit 1-2: Selected Advantages and Disadvantages of Neurostimulation Therapy Exhibit 1-3: Estimated Number of Neurostimulation Implants, by Selected Neurological Condition Exhibit 1-4: Schematic Illustration of Deep Brain Stimulation 2. NEUROSTIMULATION DEVICES 2.1 Applications for Implantable Neurostimulators 2.1.1 Chronic Pain 2.1.1.1 Boston Scientific 2.1.1.2 Medtronic 2.1.1.3 St. Jude Medical 2.1.2 Dystonia, Essential Tremor, and Parkinson's Disease 2.1.2.1 Boston Scientific 2.1.2.2 Medtronic 2.1.2.3 St. Jude Medical 2.1.3 Epilepsy 2.1.3.1 CerebralRx/BioControl Medical 2.1.3.2 Cyberonics 2.1.3.3 Medtronic 2.1.3.4 NeuroPace 2.1.3.5 NeuroSigma 2.1.3.6 NeuroVista 2.1.4 Gastroparesis 2.1.4.1 Medtronic 2.1.5 Hearing Loss 2.1.5.1 Advanced Bionics/Sonova Holding 2.1.5.2 Cochlear 2.1.5.3 MED-EL 2.1.6 Incontinence 2.1.6.1 Medtronic Exhibit 2-1: 2013, Leading Competitors in the Neurostimulation Market and the Applications for Their Products, by Condition Exhibit 2-2: The MyStim, Prime, and Restore Lines of Neurostimulators for the Treatment of Chronic Pain Exhibit 2-3: The Eon and Genesis Lines of Neurostimulators for the Treatment of Chronic Pain Exhibit 2-4: The Activa Neurostimulator for the Treatment of Parkinson's Disease and Essential Tremor Exhibit 2-5: The VNS Therapy System for the Treatment of Epilepsy Exhibit 2-6: Responsive Neurostimulation for the Suppression of Epileptic Seizures Exhibit 2-7: The Seizure Advisory System for the Prediction of Epileptic Seizures Exhibit 2-8: The Enterra Gastric Neurostimulator for the Treatment of Gastroparesis Exhibit 2-9: The HiRes 90K Implant System for the Treatment of Hearing Loss Exhibit 2-10: The Nucleus Cochlear Implant System for the Treatment of Hearing Loss Exhibit 2-11: The MAESTRO Cochlear Implant System and OPUS 2XS Audio Processor for the Treatment of Hearing Loss Exhibit 2-12: The InterStim Therapy System for the Treatment of Incontinence 3. EMERGING NEUROSTIMULATION PRODUCTS AND TECHNOLOGIES 3.1 Applications for Emerging Implantable Neurostimulators 3.1.1 Blindness 3.1.1.1 Second Sight Medical Products 3.1.1.2 Others 3.1.1.2.1 Bionic Vision Australia 3.1.1.2.2 Intelligent Medical Implants 3.1.1.2.3 Retina Implant 3.1.2 Chronic Depression 3.1.2.1 Cyberonics 3.1.2.2 Medtronic 3.1.2.3 Northstar Neuroscience 3.1.2.4 St. Jude Medical 3.1.3 Chronic Heart Failure 3.1.3.1 Medtronic 3.1.3.2 Neurotech/Sorin Group 3.1.4 Chronic Migraine Headache 3.1.4.1 Boston Scientific 3.1.4.2 Medtronic 3.1.4.3 St. Jude Medical 3.1.5 Obesity 3.1.5.1 EnteroMedics 3.1.5.2 IntraPace 3.1.5.3 MetaCure 3.1.5.4 Others 3.1.6 Sleep Apnea 3.1.6.1 Apnex Medical 3.1.6.2 Avery Biomedical Devices 3.1.6.3 ImThera Medical 3.1.6.4 Inspire Medical Systems 3.1.6.5 Respicardia 3.1.7 Other Applications 3.1.7.1 Foot Drop 3.1.7.1.1 Neurostream Technologies/Otto Bock Group 3.1.7.2 Spinal Cord Injury 3.1.7.2.1 BrainGate Company 3.1.7.2.2 Synapse Biomedical 3.1.7.3 Stroke 3.1.7.4 Tinnitus 3.1.7.4.1 MicroTransponder 3.1.7.4.2 Silere Medical Technology 3.2 Applications for Noninvasive Peripheral Nerve Stimulation 3.2.1 The Magstim Company 3.2.2 Neuronetics 3.2.3 SPR Therapeutics 3.3 Applications for Noninvasive Transcutaneous Electrical Nerve Stimulation 3.3.1 Cerbomed 3.3.2 NeuroMetrix Exhibit 3-1: The Argus Line of Intraocular Retinal Prostheses Exhibit 3-2: Bionic Vision Australia's Retinal Stimulation Technology Exhibit 3-3: Retina Implant's Subretinal Implant Technology Exhibit 3-4: The Maestro VBLOC Therapy System and Vagus Nerve Function Exhibit 3-5: The abiliti Gastric Stimulation System for the Treatment of Obesity Exhibit 3-6: The DIAMOND for the Treatment of Obesity Exhibit 3-7: The Apnex Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea Exhibit 3-8: The Mark IV Breathing Pacemaker System for the Treatment of Chronic Respiratory Insufficiency Exhibit 3-9: The aura6000 System for the Treatment of Obstructive Sleep Apnea Exhibit 3-10: An Illustration of Normal and Abnormal Breathing Patterns in Patients with Central Sleep Apnea Exhibit 3-11: The Neurostep System for the Treatment of Gait Disorders Exhibit 3-12: The Serenity System for the Treatment of Tinnitus Exhibit 3-13: The TheraStim 6000 Electronic Neurostimulation Device for the Treatment of Tinnitus Exhibit 3-14: The NeuroStar TMS Therapy System for the Treatment of Depression Exhibit 3-15: The Smartpatch PNS System for the Treatment of Chronic Shoulder Pain Exhibit 3-16: The SENSUS Pain Management System for the Treatment of Chronic Intractable Pain 4. IMPLANTABLE NEUROSTIMULATION DEVICES, MARKET ANALYSIS 4.1 Market Forecast 4.2 Implantable Neurostimulators, Competitive Analysis 4.3 Cochlear Implants, Competitive Analysis 4.4 Emerging Neurostimulation Technologies Exhibit 4-1: Selected Market Drivers and Limiters for Implantable Neurostimulation Devices Exhibit 4-2: Implantable Neurostimulation Devices (Including Cochlear Implants), Combined Market Forecast 2012-2017 Exhibit 4-3: Implantable Neurostimulation Devices (Excluding Cochlear Implants), Combined Market Forecast, 2012-2017 Exhibit 4-4: Cochlear Implants, Market Forecast, 2012-2017 Exhibit 4-5: 2012, Implantable Neurostimulation Devices Market, Estimated Percentage of Sales, by Application Exhibit 4-6: 2012, Implantable Neurostimulation Devices Market (Including Cochlear Implants), Share by Supplier Exhibit 4-7: 2012, Implantable Neurostimulation Devices Market (Excluding Cochlear Implants), Share by Supplier Exhibit 4-8: 2012, Cochlear Implants Market, Share by Supplier Exhibit 4-9: Selected Neurostimulation Devices Expected to Launch in 2013-2014 Exhibit 4-10: Selected Neurostimulation Devices Expected to Launch by the Year 2017 5. COMPANY PROFILES 5.1 Advanced Bionics Corporation/Sonova Holding AG 5.2 Boston Scientific Corporation 5.3 Cochlear LTD 5.4 Cyberonics, Inc. 5.5 EnteroMedics, Inc. 5.6 Medtronic, Inc. 5.7 Second Sight Medical Products, Inc. 5.8 St. Jude Medical, Inc. APPENDIX: COMPANY LISTING
- Advanced Bionics Corporation/Sonova Holding AG
- Apnex Medical, Inc.
- Avery Biomedical Devices, Inc.
- Bionic Vision Australia
- Boston Scientific Corporation
- BrainGate Company
- Cerbomed GmbH
- CerebralRX/BioControl Medical LTD
- Cochlear LTD
- Cyberonics, Inc.
- EnteroMedics, Inc.
- ImThera Medical, Inc.
- Inspire Medical Systems, Inc.
- IntraPace, Inc.
- The Magstim Company LTD
- MED-EL Corporation
- Medtronic, Inc.
- MetaCure LTD
- MicroTransponder, Inc.
- NeuroMetrix, Inc.
- Neuronetics, Inc.
- NeuroPace, Inc.
- NeuroSigma, Inc.
- Neurostream Technologies/Otto Bock Group
- Neurotech SA/Sorin SpA
- NeuroVista Corporation
- Respicardia, Inc.
- Retina Implant AG
- Second Sight Medical Products, Inc.
- Silere Medical Technology, Inc.
- SPR Therapeutics LLC
- St. Jude Medical, Inc.
- Synapse Biomedical, Inc.
A Single License allows for one person to access the report. A Corporate License allows for multiple individuals within a company to access the report.